Skip to main content
Clinical Trials/JPRN-UMIN000050670
JPRN-UMIN000050670
Recruiting
N/A

Exploration of biomarkers to predict the effects of anti TSLP antibody (Tezepelumab) in refractory asthma patients using comprehensive analyses of changes in gene expression in whole blood cells - Exploration of biomarkers to predict the effects of anti TSLP antibody (Tezepelumab) in refractory asthma patients using comprehensive analyses of changes in gene expression in whole blood cells

Department of Respiratory Medicine, University of Tsukuba0 sites50 target enrollmentApril 21, 2023
ConditionsSevere asthma

Overview

Phase
N/A
Intervention
Not specified
Conditions
Severe asthma
Sponsor
Department of Respiratory Medicine, University of Tsukuba
Enrollment
50
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 21, 2023
End Date
March 31, 2025
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Department of Respiratory Medicine, University of Tsukuba

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\. Patients with serious complications such as uncontrolled heart disease, diabetes mellitus, or gastrointestinal hemorrhage 2\. Patients with active local or systemic infection requiring treatment 3\. Patients with a history of serious hypersensitivity 4\. Patients whose enrollment in this study is considered to be difficult due to clinically significant psychiatric disorders 5\. Other patients considered ineligible for this study by the principal investigator/sub\-investigator

Outcomes

Primary Outcomes

Not specified

Similar Trials